Compass Therapeutics, Inc. Share Price & Technical Analysis
CMPX · $2.17 (+4.83%)
Healthcare / Biotechnology
$2.17
+4.83%
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumo…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
17% return in May, 0% avg return in past 3 year May month.
-44% return in 2026, 30% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 19% | -11% | -2% | -67% | 17% | – | – | – | – | – | – | – | -44% |
| 25 | 113% | -6% | -34% | 0% | 11% | 24% | 11% | 21% | 0% | 6% | 53% | -7% | 190% |
| 24 | -19% | 38% | 11% | -30% | -7% | -29% | 0% | 60% | 13% | -16% | -6% | -6% | 10% |
| 23 | -22% | -5% | -13% | -9% | -3% | 10% | -9% | -18% | -13% | -10% | -11% | -6% | -109% |
| 22 | -45% | 11% | -30% | 7% | 100% | -10% | 0% | 12% | -18% | 33% | 28% | 22% | 110% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$326.86M
P/E ratio
—
52W high
$6.88
52W low
$1.61
Volume
22,46,559
Beta
0.67
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Compass Therapeutics, Inc. share price today?
- Compass Therapeutics, Inc. (CMPX) last traded around $2.17 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CMPX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CMPX. Download the app for real-time alerts.
- How can I analyze Compass Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.